Home Others Others Mipomersen

research use only

Mipomersen

Cat.No.E6581

Mipomersen (ISIS 301012 free base) is an antisense oligonucleotide inhibitor of apolipoprotein B-100 (apoB-100) that causes selective degradation of apoB-100 mRNA, thereby inhibiting protein translation. This leads to reductions in low-density lipoprotein cholesterol (LDL-C) and other apoB-containing lipoprotein levels. Mipomersen is used as an adjunct treatment for homozygous familial hypercholesterolemia (FH).
Mipomersen Chemical Structure

Chemical Structure

Jump to

Quality Control

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight Formula Storage (From the date of receipt)
CAS No. 1000120-98-8 -- Storage of Stock Solutions

Read more about storage stability stock solution CAS number

Mechanism of Action

References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2019-03-26)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01475825 COMPLETED
Hypercholesterolemia; Heterozygous Familial
Kastle Therapeutics, LLC
 2011-12 PHASE3
NCT01598948 COMPLETED
Atherosclerosis; LDL-hypercholesterolemia
Ludwig-Maximilians - University of Munich
 2012-08 PHASE3
NCT00694109 COMPLETED
Lipid Metabolism, Inborn Errors; Hypercholesterolemia, Autosomal Dominant; Hyperlipidemias; Metabolic Diseases; Hyperlipoproteinemia Type II; Metabolism, Inborn Errors; Genetic Diseases, Inborn; Infant, Newborn, Diseases; Metabolic Disorder; Congenital Abnormalities; Hypercholesterolemia; Hyperlipoproteinemias; Dyslipidemias; Lipid Metabolism Disorders
Kastle Therapeutics, LLC
 2008-04 PHASE3
NCT01414881 COMPLETED
Healthy Volunteer
Kastle Therapeutics, LLC
 2011-09 PHASE1
NCT01299298 COMPLETED
Healthy Volunteer
Kastle Therapeutics, LLC
 2011-01 PHASE1
NCT00477594 COMPLETED
Lipid Metabolism, Inborn Errors; Hypercholesterolemia, Autosomal Dominant; Hyperlipidemias; Metabolic Diseases; Hyperlipoproteinemia Type II; Metabolism, Inborn Errors; Genetic Diseases, Inborn; Infant, Newborn, Diseases; Metabolic Disorder; Congenital Abnormalities; Hypercholesterolemia; Hyperlipoproteinemias; Dyslipidemias; Lipid Metabolism Disorders
Kastle Therapeutics, LLC
 2007-05 PHASE2

Read more about Clinical Trials

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.